PPARδ regulates satellite cell proliferation and skeletal muscle regeneration
© Angione et al; licensee BioMed Central Ltd. 2011
Received: 19 May 2011
Accepted: 1 November 2011
Published: 1 November 2011
Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear receptors that play important roles in development and energy metabolism. Whereas PPARδ has been shown to regulate mitochondrial biosynthesis and slow-muscle fiber types, its function in skeletal muscle progenitors (satellite cells) is unknown. Since constitutive mutation of Pparδ leads to embryonic lethality, we sought to address this question by conditional knockout (cKO) of Pparδ using Myf5-Cre/Pparδ flox/flox alleles to ablate PPARδ in myogenic progenitor cells. Although Pparδ-cKO mice were born normally and initially displayed no difference in body weight, muscle size or muscle composition, they later developed metabolic syndrome, which manifested as increased body weight and reduced response to glucose challenge at age nine months. Pparδ-cKO mice had 40% fewer satellite cells than their wild-type littermates, and these satellite cells exhibited reduced growth kinetics and proliferation in vitro. Furthermore, regeneration of Pparδ-cKO muscles was impaired after cardiotoxin-induced injury. Gene expression analysis showed reduced expression of the Forkhead box class O transcription factor 1 (FoxO1) gene in Pparδ-cKO muscles under both quiescent and regenerating conditions, suggesting that PPARδ acts through FoxO1 in regulating muscle progenitor cells. These results support a function of PPARδ in regulating skeletal muscle metabolism and insulin sensitivity, and they establish a novel role of PPARδ in muscle progenitor cells and postnatal muscle regeneration.
KeywordsCre/LoxP skeletal muscle stem cell proliferation differentiation self-renewal
Skeletal muscle is the most abundant tissue in mammals, making up 45% to 55% of total body mass in humans, and plays important roles in body movement and metabolic regulation. Muscle is made up of different fiber types which have different metabolic requirements that affect the whole body energy homeostasis of the animal . Type 1 fibers are classified as slow fibers and use oxidative metabolism as a fuel source, making them highly fatigue-resistant. Conversely, type 2 fibers are classified as fast fibers, use mainly glycolytic metabolism and are less resistant to fatigue. Type 2 fibers are further broken down into three subtypes, known as types 2a, 2x and 2b, that express corresponding myosin heavy chain (MyHC) isoforms and have decreasing resistance to fatigue. Notably, skeletal muscles are plastic, and fiber-type switching occurs in response to changes in activity and other physiological signaling pathways [2–4]. In addition, skeletal muscle mass is always in a state of hypertrophy or wasting, based on relative use or disuse, respectively [5, 6]. Skeletal muscle has superior capacity to regenerate itself upon injury .
Skeletal muscle plasticity is mainly maintained by a subset of cells known as satellite cells [8, 9]. These cells, located beneath the basal lamina of the muscle fiber, are normally maintained in a quiescent state. Satellite cells become activated when the muscle becomes damaged through injury or normal activity. Once activated the cells will reenter the cell cycle and undergo a few rounds of division, then differentiate and fuse with existing muscle fibers to rebuild the damaged area. Satellite cells in the quiescent state express paired-box transcription factor 7 (Pax7) . After activation the cells will express Pax7 and myogenic differentiation antigen 1 (MyoD) concurrently while the cells undergo a few rounds of division (proliferation). These proliferating cells eventually withdraw from the cell cycle and either return to quiescence (self-renewal) through downregulation of MyoD or differentiate through downregulation of Pax7 and upregulation of myogenin. Thus expression of Pax7 and MyoD distinguishes the status of a cell, whether it is self-renewing (Pax7+/MyoD-), proliferating (Pax7+/MyoD+) or differentiating (Pax7-/MyoD+), respectively [11–13]. Notably, researchers in several recent studies have demonstrated that the choice between self-renewal and differentiation of newly divided satellite cells is dynamically regulated [14–16]. Whereas most proliferating myoblasts divide symmetrically, a subpopulation of cells can divide asymmetrically to give rise to both self-renewal and differentiating progenies [14–16].
Myogenic factor 5 (Myf5) is also important for skeletal muscle development and satellite cell function. Myf5 transcripts can first be detected at E8 in the developing embryo and are important for specifying the cells of the muscle lineage . Myf5-Cre lineage tracing labels a majority of satellite cells, which will have become committed to the myogenic lineage. However, 10% of satellite cells remain Myf5-negative and are thought to be a population of more primitive, uncommitted stem cells that can give rise to committed cells through asymmetric cell division . Myf5-null satellite cells are defective in transient proliferation prior to differentiation [18, 19]. Intriguingly, investigators in recent studies have demonstrated that brown adipocytes, but not white adipocytes, are derived from Myf5 lineage progenitors . Therefore, Myf5-Cre-mediated conditional knockout can be used to knock out floxed target genes in committed myogenic progenitor cells and their descendants (mature skeletal muscles) as well as in brown adipocytes.
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear estrogen receptor superfamily and have been shown to be important for the proper metabolism of fatty acids . There are three PPAR isoforms (α, δ and γ), and each plays a specific role in metabolism [22–24]. The PPARs are expressed in a wide range of adult tissues, but each has its own tissue-specific expression patterns. PPARα is highly expressed in the liver and heart, PPARδ (also referred to as PPARβ, PPARβ/δ or NR1C2) is highly expressed in the intestine and liver, and PPARγ is highly expressed in both brown and white adipose tissues [21–23, 25, 26]. The three PPAR isoforms are ligand-activated receptors that are activated by fatty acids, fatty acid derivatives and a variety of synthetic compounds . The ligand-binding domains of PPARs vary slightly, resulting in specific affinity for fatty acids and synthetic compounds . For example, GW501516 is one synthetic compound that has been shown to specifically activate PPARδ with 60- to 1, 000-fold selectivity over the other isoforms, depending on cell types and animal species [28, 29]. These receptors must form heterodimers with the retinoid X receptor (RXR) before they can bind to specific recognition sequences, called PPAR response elements (PPREs), which are located in the promoter and intron regions of a wide variety of target genes [21, 30]. The PPARs activate or repress transcription through the recruitment of coactivators and corepressors.
PPARδ has been shown to be important for the proper function of skeletal muscle in gain- and loss-of-function studies. Synthetic compound-mediated activation or overexpression of the Pparδ gene in mice causes an increase in the oxidative capacity of the muscle resulting from an increase in the number of type 1 oxidative fibers and a decrease in the number of type 2 glycolytic fibers [31, 32]. These increases in oxidative capacity have been shown to contribute to an organism's overall exercise endurance. Along with increases in oxidative capacity, transgenic mice also show a decrease in overall body fat content and individual adipocyte size. Mice with constitutively active Pparδ can maintain a normal body weight even when challenged with a high-fat diet, whereas their wild-type littermates become obese when fed the same diet. By contrast, skeletal muscle-specific knockout of Pparδ seems to cause a decrease in oxidative capacity and makes mice prone to obesity and metabolic disorders . This loss of oxidative capacity could be due in part to reduced expression of PGC1α, which is known to play a role in type 1 fiber formation and maintenance. These results suggest that PPARδ plays a role in preventing obesity and the development of metabolic disorders.
Until now all the studies on PPARδ in skeletal muscle have focused on mature muscle fibers. It remains to be determined whether PPARδ plays a role in myogenic satellite cells and postnatal muscle regeneration. PPARδ has been shown to regulate the proliferation and/or maturation of several cell types, including mouse embryonic stem cells, oligodendrocytes, keratinocytes, endothelial progenitors and cancer cells [34–38]. However, whether PPARδ positively or negatively regulates proliferation is highly cell type-specific, and the evidence presented in the literature has sometimes been contradictory . In the current study, we used a Cre/LoxP-based conditional mutation approach to remove Pparδ from the satellite cells to examine its function in muscle progenitor cells. We show herein that PPARδ is an important regulator of satellite cell proliferation in vitro and of muscle regeneration in vivo.
Materials and methods
All experimental procedures involving the use of mice were carried out in accordance with Purdue University's Animal Care and Use Committee. C57BL/6J mice containing LoxP sites flanking exon 4, which encodes the N-terminal zinc finger of the DNA-binding domain of the Pparδ gene (Pparδf/f), had been generated previously . These mice were crossed with Myf5-Cre to generate Myf5-Cre/Pparδf/f offspring for ablation of Pparδ in Myf5 lineage cells (called "Pparδ-cKO" hereinafter) . Pparδ+/f or Pparδf/f littermates that did not inherit the Myf5-Cre allele were used as controls (called "wild type" hereinafter, as these mice express Pparδ normally). Genotyping was done by PCR to confirm the presence of Cre along with the presence of floxed and wild-type Pparδ alleles as described by The Jackson Laboratory under mouse stock numbers 007893 and 005897 (Bar Harbor, ME, USA).
Tibilais anterior (TA) muscles taken from six-week-old C57BL/6J mice were injured by injection of cardiotoxin (CTX) (C3987; Sigma-Aldrich, St Louis, MO, USA) to induce muscle regeneration. The animals were first anesthetized by intraperitoneal injection of 0.2 ml ketamine cocktail/20 g body weight. Ketamine cocktail contains 0.9 ml of ketamine (100 mg/ml), 0.1 ml of xylazine (100 mg/ml) and 9.0 ml of saline. The hind limbs were then shaved to expose the belly of the TA and wiped with 70% ethanol. Next we injected 50 μl of 10 μM CTX into the belly of the TA muscle. The mice were allowed to recover on a heating pad for about one hour. The mice were then harvested at days 5 and 14 after injection, and their TA muscles were removed for RNA extraction and histological examination after being fixed in 4% paraformaldehyde.
Glucose tolerance tests were performed on two- and nine-month-old mice. All mice were fasted for three hours prior to the start of testing. Blood was collected from the tip of the tail and tested before (0 minutes) and 15, 30, 60 and 90 minutes after intraperitoneal injection of glucose (2 g/kg). Blood glucose levels were measured using an ACCU-CHEK Active blood glucose meter system (Roche Diagnostics, Indianapolis, IN, USA). Body weight data were collected prior to glucose tolerance testing.
Primary myoblasts were harvested from the limb muscles of mice that were six weeks of age. Limb muscles were digested in a solution containing 1% collagenase B (Roche Diagnostics) and 2.4 U/ml Dispase II (neutral protease, grade II; Roche Applied Science) for 30 minutes in an incubator at 37°C with 5% CO2 and triturated every 15 minutes. The digestion was stopped after 30 minutes using 25 ml of DMEM containing 2% fetal bovine serum (FBS) and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, then passed through a 100-μm filter. After filtration, the cells and muscle debris were pelleted at 250 × g for five minutes and the DMEM was removed. The cells and muscle debris were then plated on noncoated plates with Ham's complete medium containing 20% FBS, 4 ng/ml basic fibroblast growth factor and 1% penicillin/streptomycin (p/s) (10, 000 U penicillin/g/ml, 10 mg streptomycin/ml). The cells and muscle debris were maintained in an incubator at 37°C with 5% CO2 for three days, and 5 ml of Ham's medium were added each day. On the third day, all cells and muscle debris (with cells attached) were collected into a 15-ml conical tube and digested with 1 ml of 0.025% trypsin for five minutes at 37°C. Dissociated cells were resuspended in 10 ml of Ham's complete medium and passed through a 30-μm filter, then plated on a collagen-coated plate. Myoblasts were maintained in Ham's medium and passed through the filter several times before they became senescent and were discarded. To differentiate myoblasts, Ham's medium was switched to DMEM containing 5% horse serum with 1% p/s when cultures reach 80% confluence. For cell-growth analysis, primary myoblasts from both Pparδ-cKO and wild-type mice were counted, and 50, 000 cells were seeded into each well of a six-well plate. Cells were removed from the plate with trypsin and counted with a hemocytometer on days 3, 6 and 9 after the initial plating.
Isolation and culture of single myofibers
Single myofiber-carrying satellite cells were isolated as previously described . Fibers were harvested from the soleus (SOL) and extensor digitorum longus (EDL) muscles of mice that were six weeks of age. Whole muscles were removed from the hind limbs by careful handling of the tendons only. The SOL and EDL muscles were first placed in 5 ml of DMEM containing 0.2% collagenase I and then into the water bath at 37°C for 40 minutes (EDL muscle) or 80 minutes (SOL muscle). The fibers were then placed into a 6-cm plate with 5 ml of DMEM and separated from the tendons by careful manipulation using heat-polished Pasteur pipettes coated with horse serum to prevent sticking. After the fibers were separated, they were fixed immediately for staining or transferred onto a new plate containing 5 ml of DMEM with 20% FBS and 2% chick embryo extract, then placed in the incubator at 37°C with 5% CO2 for three days. At the end of the three days, the fibers were collected, fixed with 2% paraformaldehyde and prepared for staining.
Primary myoblasts were grown in chamber slides for staining. The cells were fixed with 2% paraformaldehyde for ten minutes, then washed three times with PBS before the primary antibody was added. The primary antibodies used were Pax7 (Developmental Studies Hybridoma Bank, Department of Biology, University of Iowa, Iowa City, IA USA), MyoD (sc-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), and mAb clones HB287, HB277 and HB283 for MyHC1, MyHC2a and MyHC2b, respectively (American Type Culture Collection, Manassas, VA, USA). Cells were incubated with the primary antibody for one hour at room temperature on a shaker. After incubation with the primary antibody, the cells were washed three times with PBS before the secondary antibody was added. The secondary antibodies used were goat anti-mouse immunoglobulin G2b (IgG2b) conjugated with Alexa Fluor 647 dye, goat anti-mouse IgG1 conjugated with Alexa Fluor 568 dye, goat anti-mouse IgM conjugated with Alexa Fluor 488 dye (Molecular Probes/Life Technologies, Carlsbad, CA, USA) and daylight Alexa Fluor 488-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA, USA). The cells were incubated with secondary antibody and Hoechst dye (a DNA dye) for 30 minutes. The cells were again washed three times with PBS before being mounted with Dako Fluorescence Mounting Medium (Glostrup, Denmark) and covered with a coverslip. Images were recorded on a Leica DMI6000 B inverted fluorescence microscope (Leica Microsystems, Mannheim, Germany).
The muscles harvested from the hind limbs were embedded in optimal cutting temperature (O.C.T.) compound (Sakura Finetek USA Inc, Torrance, CA, USA) and quickly frozen in dry ice-cooled isopentane. Cryosections were cut to 10-μm thickness and placed on glass slides. For immunohistochemistry, slides were blocked with blocking buffer (5% horse serum, 2% BSA, 0.2% Triton X-100 and 0.1% sodium azide in PBS) for two hours prior to antibody staining. The slides were incubated with primary antibodies for one hour at room temperature, then washed three times with PBS before incubation with secondary antibody for 30 minutes. After three more washes with PBS, the slides were mounted with Dako Fluorescence Mounting Medium and covered with a coverslip.
H & E and NADH staining
Sections (10-μm thickness) were first washed with PBS to remove excess O.C.T. compound, then incubated in hematoxylin for five minutes, washed and incubated in 1% eosin for 30 seconds. The sections were then dehydrated in increasing concentrations of ethanol and mounted with CytoSeal Mounting Medium (Electron Microscopy Sciences, Fort Washington, PA, USA), covered with a coverslip and allowed to dry overnight. For nicotinamide adenine dinucleotide, reduced (NADH) staining, sections were washed briefly in PBS to remove excess O.C.T. compound. The slides were then incubated in a solution containing 100 mg/ml NADH and 0.1 g/ml nitroblue tetrazolium (NBT) for 30 minutes at 37°C. The slides were then washed three times with deionized water. Unbound NBT was removed from the sections by washing the slides three times each with 30%, 60% and 90% acetone. The sections were then washed with deionized water and mounted.
All gene expression data were gathered by real-time PCR. RNA was extracted from cell culture, whole-muscle and adipose tissue using the RNeasy RNA extraction kit (QIAGEN, Germantown, MD, USA). RNA was converted into cDNA using Moloney murine leukemia virus reverse transcriptase and random hexamer primers. The real-time PCR oligonucleotides are listed in Additional file 1, Table S1. Samples were then run in a LightCycler 480 System (Roche Applied Science) for 40 cycles. Fold changes were calculated using the 2-ΔΔCt method.
Western blot analysis
Expression of PPARδ protein in Pparδ-cKO and wild-type muscles was examined by Western blot analysis as previously described . Briefly, equal amounts of nuclear proteins extracted under identical conditions were run on SDS-PAGE gels and transferred onto polyvinylidene difluoride membrane. PPARδ was detected with rabbit anti-PPARδ antibody from Santa Cruz Biotechnology (SC-7197).
The number of mice used for each experiment is listed in the figure legend. Every experiment was performed in triplicate. For the glucose tolerance tests, statistical analysis was based on area under the curve (AUC) using the trapezoidal rule. All data are presented as means ± SEM. P-values were calculated using a two-tailed Student's t-test unless otherwise indicated. All values equal to 0.05 or less were considered significant and are denoted by asterisks in the figures.
Characterization of the Pparδ-cKO model
To generate tissue-specific knockout of Pparδ, we used mice bearing a floxed exon 4 in the Pparδ gene . The presence of Cre will excise exon 4, corresponding to the N-terminal zinc finger of the DNA binding domain of PPARδ, and lead to premature stop of translation and abolish the transcriptional activity of the resulting truncated PPARδ (Additional file 2, Figure S1A). The Pparδ f/f mice were bred to mice expressing Cre recombinase under the control of the endogenous Myf5 promoter Myf5-Cre (007893; The Jackson Laboratory) to generate the Pparδ-cKO mice. Since Myf5 is expressed in the mesoderm during development, we expected that PPARδ would be selectively ablated in several mesodermal tissues that express Myf5, including skeletal muscle and brown fat (BAT) .
To understand how PPARδ functions in muscle, we compared the expression of a number of known PPARδ target genes in wild-type and mutant TA muscles from adult mice. The expression of carnitine palmitoyltransferase 1β (mCPT1β), whose protein regulates the rate-limiting step for β-oxidation of long-chain fatty acids [21, 24], and Forkhead box class O transcription factor 1 (FoxO1), a PPARδ target that regulates skeletal muscle metabolism and progenitor cell function [42–44], were significantly decreased in Pparδ-cKO muscle (Figures 1E and 1F). The expression of several other known target genes of PPARδ, including Sirt1, UCP1 and PGC1α, was not altered in the mutant muscles (Additional file 3, Figure S2). These results confirm that Pparδ-cKO affects candidate target gene expression and identify mCPT1β and FoxO1 as potential target genes regulated by PPARδ in resting skeletal muscles.
Satellite cell and myoblast proliferation and differentiation
Next we examined whether the satellite cells associated with the isolated fibers were able to proliferate and differentiate normally using a single-myofiber culture paradigm to mimic satellite cell activation in vivo[13, 15]. We cultured isolated fibers for three days in vitro and fixed and stained clusters of myoblasts that had proliferated on single fibers with antibodies to Pax7 and MyoD (Figure 2B). Previous studies have established that Pax7+/MyoD-, Pax7+/MyoD+ and Pax7-/MyoD+ cells represent self-renewing, proliferating and differentiating progenies, respectively [11–13]. The relative percentage of cells in these three categories was examined. Compared to the wild type, mutant SOL fibers had half as many proliferating cells (Pax7+/MyoD+) and twice as many differentiating cells (MyoD+), whereas the proportion of self-renewing cells (Pax7+) remained the same between wild-type and mutant fibers (Figure 2E). Together, these results show that PPARδ is important for maintaining the proliferation of activated myoblasts and that loss of PPARδ leads to accelerated myogenic differentiation.
Muscle regeneration after injury is impaired in Pparδ-cKO animals
Because Pparδ-cKO myoblasts are defective in proliferation in vitro, we sought to determine whether such defects exist in vivo during muscle regeneration. We analyzed Pax7 and MyoD expression (Figures 4F and 4G) at days 3 to 5 post-CTX treatment, at which stage myoblast proliferation peaks. Consistent with our in vitro results, we observed a reduction of proliferating Pax7+/MyoD+ myoblasts and an increase in differentiated Pax7-/MyoD+ myocytes in the Pparδ-cKO muscle, together with reduced total myoblast number per unit area and decreased size of newly regenerated fibers (Figures 4F to 4I). In addition, we confirmed by qPCR that Myogenin gene expression was upregulated in regenerating Pparδ-cKO muscles at this stage (Figure 4J). By contrast, Myf5 was expressed at similar levels in the mutant and wild-type muscles. These results indicate that the observed regenerative defects of Pparδ-cKO may be due to reduced proliferation and increased differentiation kinetics of activated myoblasts.
We also examined the expression of mCPT1β and FoxO1 genes during muscle regeneration at day 5 after CTX treatment, when damaged muscles are not yet regenerated and satellite cell proliferation peaks . Interestingly, expression of mCPT1β was unchanged but FoxO1 expression was reduced in the Pparδ-cKO muscles compared to wild-type muscles during muscle regeneration (Figure 4E), suggesting that PPARδ may activate FoxO1 in proliferating myoblasts and that mCPT1β is a PPARδ target only in mature muscle fibers. Together with our earlier observation that Pparδ is expressed at much higher levels in proliferating myoblasts compared to mature muscles (Figure 1B), these results suggest a critical role of PPARδ in satellite cell function in vivo.
Pparδ-cKO does not alter myosin heavy chain isoforms
Old Pparδ-cKO mice become obese and have impaired glucose clearance
The results produced by our Pparδ-cKO model establish a previously unappreciated role of PPARδ in skeletal muscle progenitor cell proliferation. The specificity of the Pparδ-cKO mouse model is demonstrated by reduced Pparδ mRNA expression in both the skeletal muscle and BAT, known to be derived from Myf5 lineage cells. In contrast, Pparδ expression was unchanged in WAT, which is derived from a Myf5-independent lineage . The residual Pparδ expression detected in Pparδ-cKO whole muscle and BAT (10% to 20% of wild-type levels) is probably due to non-Myf5 lineage cells' residing in these tissues, such as nerve cells (neural branches and Schwann cells), vessel-associated cells (blood, lymph, endothelial and smooth muscle cells) and interstitial connective tissue-associated cells (fibroblasts and white adipocytes). In addition, because Myf5-Cre is expressed in about 90% of satellite cells , a small fraction of Myf5 - satellite cells would still have normal levels of Pparδ expression. We nevertheless observed proliferative defects in satellite cells in vitro and muscle regeneration in vivo. Further studies using other Cre lines with improved efficiency of Pparδ deletion in satellite cells would help to better address the muscle-regenerative defects.
Mice lacking PPARδ in their skeletal muscles are born at normal ratios and are viable. These animals do not appear to have any noticeable defects in body weight or response to glucose early in life. There was no difference in total fiber number or percentage of each fiber type in representative slow (SOL) and fast (EDL) muscles. However, old mice (eight to nine months old) were significantly fatter than their wild-type littermates and were found to have developed glucose intolerance. This phenotype in the aged mouse is similar to that reported in another transgenic mouse model in which conditional mutation of Pparδ in mature skeletal muscles is mediated by human α-skeletal actin promoter-driven Cre in the transgenic mouse . In that mouse model (Pparδ skm-/- ), a reduction in the oxidative capacity and muscle fiber-type switching are also detected, whereas such changes are not evident in the Pparδ-cKO mouse model used in our study. The discrepancy between these observations may be due to the genetic background and nutrition status (that is, diet composition) of the mice used and the different techniques used for fiber typing. The previous study used qPCR analysis to show increases in MyHC1 and MyHC2b transcripts in the gastrocnemius muscle . As many muscle fibers express multiple MyHC transcripts, small changes in these transcripts may not be sufficient to induce fiber-type switching . In our current study, we used MyHC isoform-specific mAbs to unambiguously identify fiber types, and we examined all fibers within the entire muscle to eliminate bias due to regional clustering of specific fiber types within the same muscle. We have therefore provided strong evidence that Pparδ-cKO does not lead to an overt switch of muscle fiber type in young animals based on MyHC isoform protein expression.
We show herein that the expression levels of Pax7 are significantly reduced in the whole muscle of Pparδ-cKO mice. Because Pax7 is a satellite cell-specific marker , this observation suggests a reduction in satellite cell number, which we confirmed by our later results showing that Pparδ-cKO mice have fewer satellite cells in vivo. Our single-fiber culture model that mimics satellite cell activation in vivo further demonstrates that there are fewer proliferating satellite cells and increased numbers of differentiating cells in Pparδ-cKO mice. In vitro growth and proliferation of Pparδ-cKO satellite cell-derived primary myoblasts were also reduced, as shown by the decreased number of cells expressing the cell proliferation marker Ki67 and the increased population doubling time based on the cell growth curve. Conversely, the PPARδ agonist GW501516 stimulates myoblast proliferation. These results provide compelling evidence that PPARδ acts to facilitate satellite cell proliferation.
Recent studies have shown that PPARδ promotes the proliferation of several cell types. PPARδ activation has been shown to increase the proliferation and migration of endothelial progenitors as well as the number of hematopoietic stem cells in the bone marrow [34, 47, 48]. In addition, PPARδ has been shown to be essential for high glucose-stimulated proliferation of embryonic stem cells . Moreover, PPARδ is an important regulator of the proliferation of several cancer cell types [49, 50] (older references are reviewed by Peters and Gonzalez ). The PPARδ antagonists SR13904 and GSK0660, which block PPARδ activation, have been shown to reduce cell proliferation [50, 51]. The role of PPARδ in cell proliferation has been shown to be due to its activation of the phosphatidylinositol 3-kinase and AKT pathways [34, 38], which has been shown to be important in preventing apoptosis and enhancing cell proliferation by triggering cells to overcome cell-cycle arrest and initiating cell proliferation [52, 53]. Importantly, AKT signaling plays critical roles in skeletal muscle progenitor cell function and muscle hypotrophy [4, 5, 54].
A number of other studies have shown that PPARδ promotes differentiation and inhibits (or has no effect on) proliferation in many cell types, particularly keratinocytes, smooth muscle cells, cardiac fibroblasts and several cancer cell lines (extensively reviewed by Peters and Gonzalez  and Foreman et al.). Therefore, whether PPARδ promotes terminal differentiation or cell proliferation is highly cell type-specific . Intriguingly, investigators in a recent study demonstrated that PPARδ can exert its transcriptional activation or repression both ligand-dependently and ligand-independently in a target-specific manner . Such variations in the mode of PPARδ action probably account for the paradoxical effects of PPARδ in different cell types or even in the same cell type. More research is needed to elucidate how PPARδ regulates satellite cell proliferation and whether it also functions at later stages of myogenesis (see discussion below).
Pparδ-cKO animals showed delayed muscle regeneration after injury with CTX. We found that, compared to their wild-type littermates, transgenic mice lacking PPARδ in the skeletal muscle had a reduced proportion of proliferating myoblasts and that the regenerated fibers were smaller in caliber at both five days and two weeks after CTX injury. These results are consistent with our observations that these animals had fewer satellite cells and that Pparδ-deficient satellite cells have reduced proliferative potential in vitro. Because satellite cells are responsible for skeletal muscle regeneration, reductions in satellite cell number and defective satellite cell proliferation may have resulted in the observed delay in muscle regeneration. In addition to decreased satellite cell proliferation, loss of PPARδ in myofibers may have contributed to the observed defects in muscle regeneration. Moreover, other signaling mechanisms may have compensated for the loss of PPARδ in our conditional mutant, leading to completion of muscle regeneration at a later time. Coincidentally, the incidence of sarcopenia (age-related muscle loss) has been shown to correlate with reduced levels of PPARδ, and pharmacological activation of PPARδ has been shown to reduce the incidence of sarcopenia by increasing nuclear accretion in myofibers . These results support the notion that PPARδ is important for proper skeletal muscle regeneration in response to injury or daily wear and tear (maintenance) by increasing satellite cell proliferation and promoting fusion of differentiated myocytes in vivo.
We examined the expression levels of several previously identified PPARδ target genes to understand how PPAR functions in skeletal muscle and satellite cells. Our results show that the expression of both mCPT1β and FoxO1 is reduced in mature uninjured muscles of the Pparδ-cKO mice, suggesting that they are molecular targets of PPARδ under resting conditions. Since PPARδ has been shown by many groups to be a regulator of oxidative capacity in skeletal muscle , it is not surprising that key players in the lipid oxidation pathway would be downregulated after removal of PPARδ. Interestingly, mCPT1β expression is not significantly reduced in Pparδ-cKO muscle at day 5 during regeneration. At this time point, degenerated muscle fibers have not been replaced by new fibers and myoblast proliferation is at the peak stage . This result seems to suggest that mCPT1β is a target of PPARδ in mature resting muscles, but not in proliferating myoblasts. Of all the PPARδ target genes we examined, FoxO1 was the only gene whose expression was downregulated in both resting and regenerating muscles of Pparδ-cKO mice. The downregulation of FoxO1 in Pparδ-cKO regenerating muscle indicates that FoxO1 may act at downstream of PPARδ in regulating myoblast proliferation and inhibiting its differentiation. Indeed, it has been shown that constitutive activation of FoxO1 inhibits myoblast differentiation . However, FoxO1 also acts at later stages of myogenesis, during the fusion of differentiated myocytes into myotubes . These previous studies and our present results suggest that PPARδ acts through FoxO1 in both satellite cells and mature muscle fibers but has distinct functions in these cell types. It regulates the proliferation of satellite cells and fusion of muscle fibers. These combined effects of PPARδ's acting through FoxO1 explain the regenerative defects seen in the Pparδ-cKO muscles.
PPARδ has also been implicated in the treatment of degenerative muscle diseases such as Duchenne muscular dystrophy (DMD), which is caused by the mutation of the dystrophin gene [59, 60]. One research group showed that PPARδ activation by the agonist GW501516 increased the expression of utrophin A, a key member of the dystrophin-associated protein complex, in the C2C12 myoblast cell line . PPARδ has been suggested to be a direct transcriptional regulator of utrophin A in vivo. Intriguingly, utrophin A overexpression can improve the integrity of the sarcolemma, protect muscles from contraction induced damage and help to alleviate muscle wasting and slow down the disease progression of DMD . Therefore, understanding how PPARδ functions in skeletal muscle tissue and its progenitor cells has important implications for muscle regeneration and the treatment of degenerative muscle diseases.
Our in vivo and in vitro analyses of myogenic lineage specific Pparδ gene knockouts demonstrate a critical role of PPARδ in satellite cell proliferation and postnatal regeneration of skeletal muscles. In addition, we provide evidence for a role of PPARδ in regulating muscle insulin resistance, as indicated by the glucose tolerance test results. However, we were unable to detect overt changes in skeletal muscle fiber types by MyHC isoform-specific antibody labeling. These results not only support the previously established role of PPARδ in muscle energy metabolism and insulin sensitivity but also demonstrate a novel role of PPARδ in muscle progenitor cell function. These results have implications for the treatment of muscular dystrophies and muscle-wasting conditions by targeting PPARδ signaling at the stem cell level.
bovine serum albumin
Dulbecco's modified Eagle's medium
- H & E:
hematoxylin and eosin
polymerase chain reaction.
We thank Jun Wu for mouse colony maintenance and other members of the Kuang laboratory for their comments and technical assistance. This project is partially supported by funding from the Muscular Dystrophy Association, the National Institutes of Health and the United Sates Department of Agriculture (to SK). The authors declare no conflict of interests.
- Zierath JR, Hawley JA: Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol. 2004, 2: e348-10.1371/journal.pbio.0020348.PubMed CentralView ArticlePubMed
- Rana ZA, Gundersen K, Buonanno A: Activity-dependent repression of muscle genes by NFAT. Proc Natl Acad Sci USA. 2008, 105: 5921-5926. 10.1073/pnas.0801330105.PubMed CentralView ArticlePubMed
- Serrano AL, Murgia M, Pallafacchina G, Calabria E, Coniglio P, Lømo T, Schiaffino S: Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth. Proc Natl Acad Sci USA. 2001, 98: 13108-13113. 10.1073/pnas.231148598.PubMed CentralView ArticlePubMed
- Bassel-Duby R, Olson EN: Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006, 75: 19-37. 10.1146/annurev.biochem.75.103004.142622.View ArticlePubMed
- Glass DJ: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol. 2010, 346: 267-278. 10.1007/82_2010_78.PubMed
- Pavlath GK, Horsley V: Cell fusion in skeletal muscle: central role of NFATC2 in regulating muscle cell size. Cell Cycle. 2003, 2: 420-423.View ArticlePubMed
- Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G: Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010, 120: 11-19. 10.1172/JCI40373.PubMed CentralView ArticlePubMed
- Charge SB, Rudnicki MA: Cellular and molecular regulation of muscle regeneration. Physiol Rev. 2004, 84: 209-238. 10.1152/physrev.00019.2003.View ArticlePubMed
- Kuang S, Rudnicki MA: The emerging biology of satellite cells and their therapeutic potential. Trends Mol Med. 2008, 14: 82-91. 10.1016/j.molmed.2007.12.004.View ArticlePubMed
- Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA: Pax7 is required for the specification of myogenic satellite cells. Cell. 2000, 102: 777-786. 10.1016/S0092-8674(00)00066-0.View ArticlePubMed
- Halevy O, Piestun Y, Allouh MZ, Rosser BW, Rinkevich Y, Reshef R, Rozenboim I, Wleklinski-Lee M, Yablonka-Reuveni Z: Pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewal. Dev Dyn. 2004, 231: 489-502. 10.1002/dvdy.20151.View ArticlePubMed
- Olguin HC, Olwin BB: Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev Biol. 2004, 275: 375-388. 10.1016/j.ydbio.2004.08.015.PubMed CentralView ArticlePubMed
- Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR: Muscle satellite cells adopt divergent fates: a mechanism for self-renewal?. J Cell Biol. 2004, 166: 347-357. 10.1083/jcb.200312007.PubMed CentralView ArticlePubMed
- Conboy MJ, Karasov AO, Rando TA: High incidence of non-random template strand segregation and asymmetric fate determination in dividing stem cells and their progeny. PLoS Biol. 2007, 5: e102-10.1371/journal.pbio.0050102.PubMed CentralView ArticlePubMed
- Kuang S, Kuroda K, Le Grand F, Rudnicki MA: Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell. 2007, 129: 999-1010. 10.1016/j.cell.2007.03.044.PubMed CentralView ArticlePubMed
- Shinin V, Gayraud-Morel B, Gomes D, Tajbakhsh S: Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. Nat Cell Biol. 2006, 8: 677-687. 10.1038/ncb1425.View ArticlePubMed
- Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S, Montarras D, Rocancourt D, Relaix F: The formation of skeletal muscle: from somite to limb. J Anat. 2003, 202: 59-68. 10.1046/j.1469-7580.2003.00139.x.PubMed CentralView ArticlePubMed
- Ustanina S, Carvajal J, Rigby P, Braun T: The myogenic factor Myf5 supports efficient skeletal muscle regeneration by enabling transient myoblast amplification. Stem Cells. 2007, 25: 2006-2016. 10.1634/stemcells.2006-0736.View ArticlePubMed
- Gayraud-Morel B, Chrétien F, Flamant P, Gomès D, Zammit PS, Tajbakhsh S: A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. Dev Biol. 2007, 312: 13-28. 10.1016/j.ydbio.2007.08.059.View ArticlePubMed
- Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM: PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008, 454: 961-967. 10.1038/nature07182.PubMed CentralView ArticlePubMed
- Wang YX: PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010, 20: 124-137. 10.1038/cr.2010.13.PubMed CentralView ArticlePubMed
- Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest. 2006, 116: 571-580. 10.1172/JCI27989.PubMed CentralView ArticlePubMed
- Semple RK, Chatterjee VK, O'Rahilly S: PPARγ and human metabolic disease. J Clin Invest. 2006, 116: 581-589. 10.1172/JCI28003.PubMed CentralView ArticlePubMed
- Barish GD, Narkar VA, Evans RM: PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006, 116: 590-597. 10.1172/JCI27955.PubMed CentralView ArticlePubMed
- Girroir EE, Hollingshead HE, He P, Zhu B, Perdew GH, Peters JM: Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem Biophys Res Commun. 2008, 371: 456-461. 10.1016/j.bbrc.2008.04.086.PubMed CentralView ArticlePubMed
- Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. 2001, 142: 4195-4202. 10.1210/en.142.10.4195.View ArticlePubMed
- Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CNA, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 2006, 58: 726-741. 10.1124/pr.58.4.5.View ArticlePubMed
- Shearer BG, Hoekstra WJ: Recent advances in peroxisome proliferator-activated receptor science. Curr Med Chem. 2003, 10: 267-280.View ArticlePubMed
- Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA. 2001, 98: 5306-5311. 10.1073/pnas.091021198.PubMed CentralView ArticlePubMed
- Napal L, Marrero PF, Haro D: An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. J Mol Biol. 2005, 354: 751-759. 10.1016/j.jmb.2005.09.097.View ArticlePubMed
- Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA: Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J. 2003, 17: 2299-2301.PubMed
- Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM: Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2004, 2: e294-10.1371/journal.pbio.0020294.PubMed CentralView ArticlePubMed
- Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, Metzger D: PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab. 2006, 4: 407-414. 10.1016/j.cmet.2006.10.003.View ArticlePubMed
- Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS: Peroxisome proliferator-activated receptor-δ agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation. 2008, 118: 1021-1033. 10.1161/CIRCULATIONAHA.108.777169.View ArticlePubMed
- Kim YH, Han HJ: High-glucose-induced prostaglandin E2 and peroxisome proliferator-activated receptor δ promote mouse embryonic stem cell proliferation. Stem Cells. 2008, 26: 745-755. 10.1634/stemcells.2007-0786.View ArticlePubMed
- Peters JM, Gonzalez FJ: Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta. 2009, 1796: 230-241.PubMed CentralPubMed
- Simonini MV, Polak PE, Boullerne AI, Peters JM, Richardson JC, Feinstein DL: Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ASN Neuro. 2010, 2: e00025-10.1042/AN20090051.
- Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, DuBois RN: Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc Natl Acad Sci USA. 2006, 103: 19069-19074. 10.1073/pnas.0607948103.PubMed CentralView ArticlePubMed
- Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM: Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA. 2002, 99: 303-308. 10.1073/pnas.012610299.PubMed CentralView ArticlePubMed
- Tallquist MD, Weismann KE, Hellström M, Soriano P: Early myotome specification regulates PDGFA expression and axial skeleton development. Development. 2000, 127: 5059-5070.PubMed
- Rosenblatt JD, Lunt AI, Parry DJ, Partridge TA: Culturing satellite cells from living single muscle fiber explants. In vitro Cell Dev Biol Anim. 1995, 31: 773-779. 10.1007/BF02634119.View ArticlePubMed
- Nahlé Z, Hsieh M, Pietka T, Coburn CT, Grimaldi PA, Zhang MQ, Das D, Abumrad NA: CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR δ/β-mediated adaptation to metabolic stress. J Biol Chem. 2008, 283: 14317-14326. 10.1074/jbc.M706478200.PubMed CentralView ArticlePubMed
- Wagner KD, Wagner N: Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther. 2010, 125: 423-435. 10.1016/j.pharmthera.2009.12.001.View ArticlePubMed
- Kitamura T, Kitamura YI, Funahashi Y, Shawber CJ, Castrillon DH, Kollipara R, DePinho RA, Kitajewski J, Accili D: A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest. 2007, 117: 2477-2485. 10.1172/JCI32054.PubMed CentralView ArticlePubMed
- Wang LC, Kernell D: Recovery of type I fiber regionalization in gastrocnemius medialis of the rat after reinnervation along original and foreign paths, with and without muscle rotation. Neuroscience. 2002, 114: 629-640. 10.1016/S0306-4522(02)00315-9.View ArticlePubMed
- Waddell JN, Zhang P, Wen Y, Gupta SK, Yevtodiyenko A, Schmidt JV, Bidwell CA, Kumar A, Kuang S: Dlk1 is necessary for proper skeletal muscle development and regeneration. PLoS One. 2010, 5: e15055-10.1371/journal.pone.0015055.PubMed CentralView ArticlePubMed
- He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS: Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res. 2008, 103: 80-88. 10.1161/CIRCRESAHA.108.176057.PubMed CentralView ArticlePubMed
- Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D: Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2007, 27: 63-69. 10.1161/01.ATV.0000250972.83623.61.View ArticlePubMed
- Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK, Noy N: Fatty acid-binding protein 5 and PPARβ/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem. 2010, 285: 19106-19115. 10.1074/jbc.M109.099770.PubMed CentralView ArticlePubMed
- Zaveri NT, Sato BG, Jiang F, Calaoagan J, Laderoute KR, Murphy BJ: A novel peroxisome proliferator-activated receptor δ antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol Ther. 2009, 8: 1252-1261. 10.4161/cbt.8.13.8691.View ArticlePubMed
- Wagner KD, Benchetrit M, Bianchini L, Michiels JF, Wagner N: Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation. J Pathol. 2011, 224: 575-588. 10.1002/path.2910.View ArticlePubMed
- Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 1999, 96: 2110-2115. 10.1073/pnas.96.5.2110.PubMed CentralView ArticlePubMed
- Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N: Activation of Akt/protein kinase B overcomes a G2/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002, 22: 7831-7841. 10.1128/MCB.22.22.7831-7841.2002.PubMed CentralView ArticlePubMed
- Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW: Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3'-kinase/Akt signaling pathway. J Biol Chem. 2000, 275: 35942-35952. 10.1074/jbc.M005832200.View ArticlePubMed
- Foreman JE, Sharma AK, Amin S, Gonzalez FJ, Peters JM: Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Lett. 2010, 288: 219-225. 10.1016/j.canlet.2009.07.006.PubMed CentralView ArticlePubMed
- Adhikary T, Kaddatz K, Finkernagel F, Schönbauer A, Meissner W, Scharfe M, Jarek M, Blöcker H, Müller-Brüsselbach S, Müller R: Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). PLoS One. 2011, 6: e16344-10.1371/journal.pone.0016344.PubMed CentralView ArticlePubMed
- Giordano C, Rousseau AS, Wagner N, Gaudel C, Murdaca J, Jehl-Piétri C, Sibille B, Grimaldi PA, Lopez P: Peroxisome proliferator-activated receptor β activation promotes myonuclear accretion in skeletal muscle of adult and aged mice. Pflügers Arch. 2009, 458: 901-913. 10.1007/s00424-009-0676-9.PubMed CentralView ArticlePubMed
- Bois PRJ, Grosveld GC: FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 2003, 22: 1147-1157. 10.1093/emboj/cdg116.PubMed CentralView ArticlePubMed
- Hoffman EP, Brown RH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987, 51: 919-928. 10.1016/0092-8674(87)90579-4.View ArticlePubMed
- Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AH, Belfall B, Klamut HJ, Talbot J, Hodges RS, Ray PN, Worton RG: The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature. 1988, 333: 466-469. 10.1038/333466a0.View ArticlePubMed
- Miura P, Chakkalakal JV, Lunde J, Shaver A, Belanger G, Jasmin BJ: Activation of PPARδ stimulates utrophin A expression in skeletal muscle cells. FASEB J. 2007, 21: A1301-A1302.
- Miura P, Chakkalakal JV, Boudreault L, Bélanger G, Hébert RL, Renaud JM, Jasmin BJ: Pharmacological activation of PPARβ/δ stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet. 2009, 18: 4640-4649. 10.1093/hmg/ddp431.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.